Search results
Found 79 matches for
Circadian Therapeutics, a life sciences spinout of Oxford University, has been established to identify and bring to market pharmaceutical and diagnostic platforms for the effective management of physiological and pathological conditions through their ability to modify the body's circadian rhythms.
©
Pollar SD - Shutterstock
Human challenge trial launches to study immune response to COVID-19
Clinical Trials Coronavirus COVID-19 General
19 April 2021
Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.
Alternating vaccines trial expands to include two additional vaccines
Clinical Trials Coronavirus COVID-19 General
14 April 2021
Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19
Clinical Trials Coronavirus COVID-19 Research
12 April 2021
Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.
University of Oxford to study nasal administration of COVID-19 vaccine
Clinical Trials Coronavirus COVID-19 General
26 March 2021
The University of Oxford is launching a study investigating the delivery of the ChAdOx1 nCoV-19 coronavirus vaccine using a nasal spray.
AstraZeneca publish primary analysis from US trial of coronavirus vaccine
Clinical Trials Coronavirus COVID-19 General Research
25 March 2021
Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective
Clinical Trials Coronavirus COVID-19 General Research
22 March 2021
A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.
PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine
Clinical Trials Coronavirus COVID-19 General Research
3 March 2021
From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.
World’s largest clinical trial for COVID-19 treatments expands internationally
Clinical Trials Coronavirus COVID-19 General
18 February 2021
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.
World Health Organization lists Oxford coronavirus vaccine for emergency use
Clinical Trials Coronavirus COVID-19 General
15 February 2021
The Oxford / AstraZeneca vaccine has today been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunisation to prevent COVID-19 in individuals 18 years of age and older, including those over 65.
Oxford University extends COVID-19 vaccine study to children
Clinical Trials Coronavirus COVID-19 General
12 February 2021
The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.
Drug trial that could improve respiratory recovery from COVID-19 now underway
Clinical Trials Coronavirus COVID-19 General
10 February 2021
A clinical trial has commenced this week to test whether a drug called Almitrine can help people who are seriously ill with COVID-19 to recover from the disease.
ChAdOx1 nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young South African adults
Clinical Trials Coronavirus COVID-19 General
8 February 2021
In an analysis, submitted as a pre-print prior to peer-review publication, a two-dose regimen of the ChAdOx1 nCoV-19 vaccine provides minimal protection against mild-moderate COVID-19 infection from the B.1.351 coronavirus variant first identified in South Africa.
Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK
Clinical Trials Coronavirus COVID-19 General
5 February 2021
A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.
Oxford leads first trial investigating dosing with alternating vaccines
Clinical Trials Coronavirus COVID-19 General
4 February 2021
The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
Oxford coronavirus vaccine shows sustained protection of 76% during the 3-month interval until the second dose
Clinical Trials Coronavirus COVID-19 General Research
2 February 2021
Researchers at the University of Oxford have today published in Preprints with The Lancet an analysis of further data from the ongoing trials of the vaccine. In this, they reveal that the vaccine efficacy is higher at longer prime-boost intervals, and that a single dose of the vaccine is 76% effective from 22- to up to 90-days post vaccination.
RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19
Clinical Trials Coronavirus COVID-19 General Research
18 January 2021
The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19.
Oxford University welcomes UK regulatory emergency use authorisation of coronavirus vaccine
Clinical Trials Coronavirus COVID-19 General Research
30 December 2020
The University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.
Oxford vaccine stimulates broad antibody and T cell functions
Clinical Trials Coronavirus COVID-19 Research
17 December 2020
Today, researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.
First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy
Clinical Trials Coronavirus COVID-19 General Research
8 December 2020
Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
Oxford coronavirus vaccine produces strong immune response in older adults
Clinical Trials Coronavirus COVID-19 General Research
19 November 2020
The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.